How to administer SINGULAIR oral granules to appropriate pediatric patients
SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older.
SELECTED SAFETY INFORMATION
- SINGULAIR is contraindicated in patients with hypersensitivity to any component of this product.
- Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.
OPEN the packet of SINGULAIR 4-mg oral granules.
- Do not open the packet until you are ready to give SINGULAIR 4-mg oral granules to the patient.
- Contents of 1 packet=1 dose.
For more details on the timing of dosing, please read the Dosage and Administration section of the
Prescribing Information.
SELECTED SAFETY INFORMATION (continued)
- SINGULAIR should not be used as rescue medication to treat acute asthma attacks. Patients should be advised to have appropriate rescue medication available.
- While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, SINGULAIR should not be abruptly substituted for inhaled or oral corticosteroids.
- Patients receiving SINGULAIR should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
Please see Selected Safety Information about SINGULAIR.
Before prescribing SINGULAIR, please read the Prescribing Information.
RESP-1007091-0003 01/12